Biodesix Presents Data From Three Studies at AACR Annual Meeting BOULDER, Colo., April 05, 2017 (GLOBE NEWSWIRE) -- Biodesix is presenting three studies that support the company’s multi-omic capabilities and provide insight into the biology of classifiers...

New Data Show Biodesix’s VeriStrat® Test is Cost-Saving, Improves Survival and Quality of Life in Advanced Lung-Cancer Patients BOULDER, Colo., April 03, 2017 (GLOBE NEWSWIRE) -- Biodesix®, Inc. announced today new data demonstrating that use of the VeriStrat® test in patients with advanced non-small cell lung cancer (NSCLC)...

New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life BOULDER, Colo., March 22, 2017 (GLOBE NEWSWIRE) -- Biodesix®, Inc. announced today the results of a study demonstrating that the use of the VeriStrat® test for patients with non-small cell lung...

Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber BOULDER, Colo., March 20, 2017 (GLOBE NEWSWIRE) -- Dr. Jeffery Weber will present data from a collaboration in which proteomic tests developed by Biodesix® could help guide therapy choices in...

Biodesix® and Progenetics Announce Distribution Agreement for Israel BOULDER, Colo., March 09, 2017 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Boulder, CO, USA) and Progenetics LTD (Tel Aviv, Israel) announced today that they have entered into an international agreement...